GAMMAL HASSANIEN: Open Payments
NPI 1528262961 · PATERSON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,718 in 47 payments from 14 companies in 2025. Trend: 2023 $1,673 · 2024 $1,760 · 2025 $2,718
Food & beverage: $2,718
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 20 | $1,036 |
| AstraZeneca Pharmaceuticals LP | 5 | $397 |
| Corcept Therapeutics | 4 | $296 |
| Amgen Inc. | 2 | $225 |
| ABBVIE INC. | 1 | $125 |
| Novo Nordisk Inc | 1 | $125 |
| Braeburn Inc. | 1 | $122 |
| ABIOMED | 1 | $113 |
| Bard Peripheral Vascular, Inc. | 1 | $77 |
| Dexcom, Inc. | 3 | $65 |
Products named: REZDIFFRA, Korlym, AIRSUPRA, BREZTRI, MAVYRET, Ozempic, Repatha, BRIXADI.
Industry payments across NJ — which companies pay providers there.
